Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
about
Gab2 mediates hepatocellular carcinogenesis by integrating multiple signaling pathways.How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety.BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines.
P2860
Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Axitinib and sorafenib are pot ...... chronic myeloid leukemia cells
@en
type
label
Axitinib and sorafenib are pot ...... chronic myeloid leukemia cells
@en
prefLabel
Axitinib and sorafenib are pot ...... chronic myeloid leukemia cells
@en
P2093
P2860
P50
P1476
Axitinib and sorafenib are pot ...... chronic myeloid leukemia cells
@en
P2093
Christine Gretzmeier
Franziska U Wöhrle
Julia Ellermann
P2860
P2888
P356
10.1186/S12964-016-0129-Y
P577
2016-02-24T00:00:00Z
P5875
P6179
1032761627